Kornimate/medical-research-clean huggingface dataset:
nabilone & marijuana addiction

Conditions: Marijuana Smoking

Summary: safety of nabilone in reducing marijuana craving

randomized double blind trial into the safety and efficacy of cesemat for the treatment of marijuana use

Eligibility criteria:
inclusion criteria: * 19 years or older * history of marijuana use

Keywords: efficacy marijuana reduction craving
lipoprotein interactions and platelet function in healthy individuals and those with lipid disorders

Conditions: Lipid Disorders

Summary: this study looks at how lipoproteins, which are particles in the blood that transport cholesterol, influence heart and blood vessel health. beyond just their levels, the way these particles function plays a key role in preventing or contributing to disease. in some conditions, like high cholesterol or diabetes, lipoproteins may not work properly, increasing the risk of clogged arteries and other complications. the investigators aim to study these changes in people with lipid disorders to better understand their impact on blood health and to find new ways to prevent and treat heart disease.

traditionally, lipoproteins have been associated with cardiovascular protection, but emerging research indicates that their functionality may be a more critical factor than their levels in evaluating cardiovascular risk. lipoproteins, such as hdl, ldl, and vldl, play vital roles in processes like reverse cholesterol transport and demonstrate anti-inflammatory, antioxidative, and antiplatelet properties. however, in conditions like atherosclerosis, diabetes, and dyslipidemia, these lipoproteins often become dysfunctional, and the mechanisms behind this dysfunction remain incompletely understood. this study aims to thoroughly investigate the pathogenic roles of lipoproteins by examining their structural and functional modifications and their influence on platelet activity in individuals with lipid disorders.

Eligibility criteria:
inclusion criteria: * healthy volunteers * abnormalities in lipid panels * able to provide informed consent * between the age of 18 and 69 exclusion criteria: * drug or alcohol abuse within 6 months or significant mental/psychological impairment * current smokers * subjects with known bleeding disorders (for example, hemophilia) * subjects requiring regular transfusions for any reason * no ethnic/racial groups will be excluded

Keywords: lipids lipoproteins platelets high cholesterol
a study for monthly methoxy polyethylene glycol-epoetin beta treatment in patients with chronic renal anaemia

Conditions: Anemia

Summary: this open-label single-arm study will evaluate the efficacy, safety and tolerability of methoxy polyethylene glycol epoetin beta on long-term maintenance of haemoglobin levels in patients with chronic renal anaemia. patients will receive methoxy polyethylene glycol-epoetin beta intravenously once monthly at initial doses of either 120 micrograms or 200 micrograms or 360 micrograms in the titration phase of 16 weeks with a potential dose adjustment in the evaluation phase of 8 weeks. the anticipated time on study treatment is 24 weeks. the target sample size is 50-100 patients.


Eligibility criteria:
inclusion criteria: * adults \>/=18 years of age * chronic renal anaemia * haemoglobin concentration between 10 and 12 g/dl at screening * adequate iron status * continuous intravenous maintenance short-acting therapy with same dosing interval for 8 weeks prior to screening * regular long-term haemodialysis therapy for at least 12 weeks prior to screening exclusion criteria: * change in haemoglobin concentration \>/=2 g/dl during screening * transfusion of red blood cells less than 8 weeks prior to screening * poorly controlled hypertension * relevant acute or chronic bleeding requiring treatment less than 8 weeks prior to screening * active malignant disease * haemolysis * haemoglobinopathies
a study of moderate to severe inflammatory bowel disease, including ulcerative colitis (uc) and crohn's disease (cd)

Conditions: Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease

Summary: the main aim of this study is to check the disease activity in people with moderate to severe ulcerative colitis and crohn's disease. participants will complete questionnaires about their disease and quality of life on day 1 clinic visit. they will do this during a standard scheduled appointment with their doctor. some of this study will also involve collecting information about participants from their medical records.

this is a retrospective, cross-sectional, and non-interventional study of participants with moderate to severe ibd (uc or cd). the study will have a cross-sectional evaluation on day 1 to provide the real-world data of disease activity, treatment patterns, burden of disease and quality of life in participants with moderate to severe uc or cd. the study will involve an additional retrospective review of medical charts of participants of previous 3 years to describe the ibd treatments and use of other healthcare resources related with the management of uc or dc. the study will enroll approximately 335 participants. all participants will be enrolled in one observational cohort. this multi-center trial will be conducted in mexico. the overall time for data collection in the study will be approximately 3 years before the start of the study (day 1).

Eligibility criteria:
inclusion criteria: 1. diagnosed with moderate to severe cd or uc established for at least 6 months prior to day 1 appointment, based on clinical, endoscopic or image criteria. 2. participants aged 18 years or older (at the time of diagnosis of moderate to severe uc or cd). exclusion criteria: 1. has indeterminate or not classified colitis. 2. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Keywords: drug therapy
investigating the central and peripheral mechanisms by which glucocorticoids affect hunger

Conditions: Obesity

Summary: the purpose of this study is to examine if glucocorticoids will change neural activation in regions of the corticolimbic-striatal system that regulate feeding.

the primary hypothesis tested in this study will be to determine if that in response to food cues, glucocorticoids will change neural activation in regions of the corticolimbic-striatal system that regulate feeding. it is anticipate that these changes will correlate with hunger ratings and food intake. further, this research will also examine if glucocorticoids will increase the basal metabolic rate and alter multiple systemic appetite-regulating hormones compared to saline. it is expected that these changes will correlate positively with hunger ratings and food intake as well.

Eligibility criteria:
inclusion criteria: * bmi \< = 26 kg/m2 * ability to read and write english exclusion criteria: * creatinine \> 1.5 * hgb \< 10 mg/dl * alt \> 2.5 x uln * untreated thyroid disease * uncontrolled or severe hypertension * known neurological disorders * diabetes or impaired glucose tolerance * untreated or severe psychiatric disorders * malignancy * endogenous hypercortisolism * addison's disease * bleeding disorders * smoking * current or recent steroid use in the last 3 months * illicit drug use * eating disorders * drug or alcohol addiction * history of claustrophobia * pregnancy * breastfeeding * contraindications to mri * use of any psychoactive medication within the past 3 months

Keywords: fmri obesity
preliminary antitumor activity, safety and tolerability of tislelizumab in combination with lenvatinib for hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Unresectable Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma

Summary: the primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (orr) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (hcc) by central site imaging facility per response evaluation criteria in solid tumors (recist) version 1.1.


Eligibility criteria:
key inclusion criteria: 1. able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments 2. unresectable locally advanced or metastatic hcc, which must be confirmed by histologically or cytologically. fibrolamellar, sarcomatoid, or mixed cholangiocarcinoma histology confirmed by histologically or cytologically is excluded. 3. barcelona clinic liver cancer (bclc) stage c disease or bclc stage b disease that is not amenable to or has progressed after loco-regional therapy and is not amenable to a curative treatment approach 4. did not receive any systemic treatment before and is unwilling to accept standard of care treatment or not suitable for standard of care treatment as judged by investigators 5. at least 1 measurable lesion as defined by recist v1.1 6. european cancer oncology group (ecog) performance status ≤ 1 7. child-pugh a classification for liver function assessed within 7 days of first dose of study drugs key exclusion criteria: 1. active autoimmune diseases or history of autoimmune diseases that may relapse 2. any active malignancy ≤ 2 years before the first dose of study drugs except for specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast) 3. uncontrolled diabetes or \> grade 1 laboratory test abnormalities in potassium, sodium, or corrected calcium despite standard medical management, or ≥ grade 3 hypoalbuminemia ≤ 14 days before the first dose of study drugs 4. any known brain or leptomeningeal metastases 5. concurrent participation in another therapeutic clinical study not: other protocol defined inclusion/exclusion criteria may apply note: other protocol defined inclusion/exclusion criteria may apply.
registry of covid-19 patients treated with the seraph 100 microbind affinity blood filter

Conditions: COVID-19

Summary: the purpose of this registry study is to investigate the effectiveness and safety of the seraph® 100 microbind® affinity blood filter (seraph 100) in the treatment of covid-19 patients.

during the ongoing covid-19 pandemic, millions of people have been infected with sars- cov-2 worldwide. in the absence of an approved vaccine or medical treatment, there is an emerging need for treatment options, especially in critically ill patients. multiple pharmacological and non-pharmacological therapies are being investigated. in 2019, the seraph® 100 microbind® affinity blood filter (exthera medical corporation, ca, usa) was approved for the removal of pathogens in europe. on april 17th the fda granted authorization for emergency use in patients with covid-19 admitted to the icu with confirmed or imminent respiratory failure.

Eligibility criteria:
inclusion criteria: * covid-19 infection * treatment with the seraph® 100 microbind® affinity blood filter * voluntary consent to participate in registry exclusion criteria: - none
validation of tbi detection system for head injured patients

Conditions: Brain Injuries

Summary: a prospective, non-randomized trial to validate the database of brain electrical activity recordings and clinical information collected from patients who present to the ed following closed head injury.

the objective of this study is to validate the clinical utility of the brainscope technology for the acute identification of structural brain injuries in a tbi population presenting to the ed with mild symptoms, following closed head injury.

Eligibility criteria:
inclusion criteria: * subjects who are admitted to the ed and are suspected of a traumatic, closed head injury within 72 hours. the patient will have a gcs 12-15 upon arrival to the ed even if gcs was lower prior to arrival to the ed (e.g., at the time of injury). exclusion criteria: * subjects will be excluded who have forehead, scalp, or skull abnormalities or other conditions that would prevent correct application of the electrode headset on the skin. * in addition, * subjects with dementia, * parkinson's disease, * multiple sclerosis, * seizure disorder, * brain tumors, * history of brain surgery, * evidence of acute psychosis, * substance dependence, * history of tia or stroke within the last year, * currently receiving dialysis or in end-stage renal disease, * active fever defined as greater than 100 degrees f or 37.7 degrees c, * current condition is "critical" in the opinion of the investigator, * subject is suffering from an open head injury, * subject requires advanced airway management (i.e. mechanical ventilation), * currently receiving procedural sedation medications. * subjects below the age of 18 years, and prisoners will not be eligible for study.
osteoporosis research registry

Conditions: Osteoporosis

Summary: the aim of this research registry is to collect information on individuals with osteoporosis, those with risk factors for osteoporosis, and comparative healthy controls. bone mineral density measurements will be done on these individuals to determine bone health.

the goal of this project is to develop a registry of research subjects with op, with a risk of developing op, and healthy controls. dxa scans will be performed on willing individuals at the spine, hips, and forearms and possibly the legs and heels in order to determine bmd. subjects will also be asked to provide two (10 ml) blood samples, which may be used to analyze vitamin d levels and/or other bone markers. by participating in the registry, subjects will be considered for current and future clinical research studies.

Eligibility criteria:
inclusion criteria: * any subjects who give written informed consent exclusion criteria: * any individual who is not willing or able to give written informed consent
the investigation into beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in moderate to severe covid-19

Conditions: Covid19

Summary: the present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming covid-19 in loghman hakim medical education center in tehran. patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

according to previous studies, ifn-β has strong antiviral activity and also has an acceptable safety profile. based on possible therapeutic effects, we decided to lead an investigation into beneficial effects of high-dose interferon beta 1a, compared to low-dose interferon beta 1a (the base therapeutic regimen) in moderate to severe covid-19. previous studies demonstrate that ifn-β 1a could be used against some coronaviruses including avium infectious, bronchitis virus, murine hepatitis virus, and sars- cov because they are susceptible in vitro or in vivo. in a current study, the efficacy of ifn-β 1a in covid-19 patients were evaluated, and they found than ifn-β 1a reduced the disease symptoms. the present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming covid-19 in loghman hakim medical education center in tehran.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * covid-19 confirmed cases (either rt-pcr or ct scan confirmed) * at least one of the following: radiation contactless body temperature ≥37.5, cough, shortness of breath, nasal congestion/ discharge, myalgia/arthralgia, diarrhea/vomiting, headache or fatigue on admission. * time of onset of the symptoms should be acute (days ≤ 14) * news2 ≥ 1 on admission (national early warning score 2) exclusion criteria: * refusal to participate expressed by patient or legally authorized representative if they are present * patients using drugs with potential interaction with lopinavir/ritonavir or interferon-β 1a * pregnant or lactating women. * history of alcohol or drug addiction in the past 5 years. * blood alt/ast levels \> 5 times the upper limit of normal on laboratory results. * the patients who were intubated less than one hours after admission to the hospital

Keywords: covid-19 interferons ritonavir lopinavir interferon-beta antiviral agents anti-infective agents immunologic factors
phil® embolic system pediatric ide

Conditions: Arterio-venous Fistula; Intracranial Arteriovenous Malformations

Summary: the purpose of this study is to collect information about how the phil® embolic system works in the treatment of intracranial dural arteriovenous fistulas. data collected in this study will be used to evaluate the safety and probable benefits in treating davfs. the phil® embolic system is a humanitarian use device (hud). the u.s. food and drug administration (fda) approved the use of the phil embolic system as a hud in june 2016.

study design:the study is a prospective, single-center, single-arm, clinical study evaluating outcomes in pediatric subjects with intracranial dural arteriovenous fistulas treated with phil® device. study purpose: to evaluate the safety and probable benefit of microvention, inc. phil® liquid embolic material in the treatment of intracranial dural arteriovenous fistulas, alone or as an adjunctive treatment for davfs.

Eligibility criteria:
inclusion criteria: * subject is \<22 years of age * subject and legally authorized representative are willing and capable of complying with all study protocol requirements, including specified follow-up period. * subject's legally authorized representative(s) must sign and date an irb approved written informed consent prior to initiation of any study procedure * subject has an intracranial davf that is deemed appropriate for embolization with phil without significantly increased risk to collateral or adjacent territories, or subject has been previously treated with other embolic materials for davf. exclusion criteria: * subject presents with an intracranial mass or is currently undergoing radiation therapy for carcinoma or sarcoma of the head or neck region * subject has known allergies to dmso (dimethyl sulfoxide), iodine or heparin. * subject with a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated). * female subject is currently pregnant. * subject has an acute or chronic life-threatening illness other than the neurological disease to be treated in this study including but not limited to any malignancy or debilitating autoimmune disease * subject has existing severe or advanced comorbid conditions which significantly increase general anesthesia and/ or surgical risk * evidence of active infection at the time of treatment. * subject has a history of bleeding diathesis or coagulopathy, international normalized ratio (inr) greater than 1.5, or will refuse blood transfusions. * subject weighs ≤ 2.5kg angiographic * subject has severe calcification or vascular tortuosity that may preclude the safe introduction of the sheath, guiding catheter, or access to the lesion with the microcatheter. * contra-indication to dsa, ct scan or mri/ mra * history of intracranial vasospasm not responsive to medical therapy * extra-cranial stenosis or parent vessel stenosis \> 50% proximal to the target lesion to be treated. * subject has a propensity to contrast induced renal injury or a potential to nephrogenic systemic fibrosis

Keywords: pediatric
clinical efficacy between robotic and laparoscopic total gastrectomy in patients with clinical stage i gastric cancer

Conditions: Stomach Neoplasm; Robotic Surgery

Summary: the purpose of this study is to explore the clinical efficacy between robotic and laparoscopic total gastrectomy in patients with clinical stage i gastric cancer

robotic surgery has been developed with the aim of improving surgical quality and overcoming the limitations of conventional laparoscopy in the performance of complex mini-invasive procedures. the study is designed to explore the clinical outcomes of the robotic assisted total gastrectomy by comparing short- and long-term outcomes including financial cost of robotic and laparoscopic assisted total gastrectomy in the treatment of clinical stage i gastric adenocarcinoma （cstage ia（t1n0m0）or cstage ib（t1n1m0，t2n0m0））.

Eligibility criteria:
inclusion criteria: * age from over 18 to under 75 years * primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cstage ia（t1n0m0）or cstage ib（t1n1m0，t2n0m0）at preoperative evaluation according to the american joint committee on cancer (ajcc) cancer staging manual 8th edition * the tumor is on the upper or middle third stomach and expected to perform total gastrectomy with d1+/d2-10 lymph node dissction to obtain r0 resection sugicall results. * performance status of 0 or 1 on ecog (eastern cooperative oncology group) scale * asa (american society of anesthesiology) class i to iii * written informed consent exclusion criteria: * cstage iia or more advaned at preoperative evaluation according to the american joint committee on cancer (ajcc) cancer staging manual 8th edition * women during pregnancy or breast-feeding * severe mental disorder * history of previous upper abdominal surgery (except laparoscopic cholecystectomy) * multiple primary cancer * history of previous gastric surgery (except esd/emr (endoscopic submucosal dissection/endoscopic mucosal resection )for gastric cancer) * gastric multiple primary carcinoma * enlarged or bulky regional lymph node （diameter over 3cm）supported by preoperative imaging * history of other malignant disease within the past 5 years * history of previous neoadjuvant chemotherapy or radiotherapy * history of unstable angina or myocardial infarction within the past 6 months * history of cerebrovascular accident within the past 6 months * history of continuous systematic administration of corticosteroids within 1 month * requirement of simultaneous surgery for other disease * emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer * fev1\<50% of the predicted values

Keywords: stomach neoplasm robotic surgery total gastrectomy